7NS0 logo

Palisade Bio DB:7NS0 Stock Report

Last Price

€5.01

Market Cap

€4.0m

7D

0%

1Y

-78.5%

Updated

03 Jul, 2024

Data

Company Financials +

7NS0 Stock Overview

A clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. More details

7NS0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Palisade Bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Palisade Bio
Historical stock prices
Current Share PriceUS$5.01
52 Week HighUS$30.82
52 Week LowUS$4.75
Beta1.29
1 Month Change0%
3 Month Change0.12%
1 Year Change-78.46%
3 Year Change-99.77%
5 Year Changen/a
Change since IPO-99.89%

Recent News & Updates

Recent updates

Shareholder Returns

7NS0DE PharmaceuticalsDE Market
7D0%-1.7%-1.6%
1Y-78.5%-15.8%6.8%

Return vs Industry: 7NS0 underperformed the German Pharmaceuticals industry which returned -17.7% over the past year.

Return vs Market: 7NS0 underperformed the German Market which returned 6.1% over the past year.

Price Volatility

Is 7NS0's price volatile compared to industry and market?
7NS0 volatility
7NS0 Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 7NS0 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 7NS0's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a9J. Finleywww.palisadebio.com

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy.

Palisade Bio, Inc. Fundamentals Summary

How do Palisade Bio's earnings and revenue compare to its market cap?
7NS0 fundamental statistics
Market cap€3.96m
Earnings (TTM)-€12.57m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7NS0 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$13.50m
Earnings-US$13.50m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-14.42
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 7NS0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/03 04:37
End of Day Share Price 2024/04/05 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Palisade Bio, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Aydin HuseynovLadenburg Thalmann & Company
Jason McCarthyMaxim Group